The team of Prof. Zhenjun Yang have made continuous progress in the delivery of antisense nucleic acid structural modifications in vivo and the treatment of liver cancer

Journal of Chinese Pharmaceutical Sciences ›› 2023, Vol. 32 ›› Issue (7): 598-599.

• News • Previous Articles Next Articles

The team of Prof. Zhenjun Yang have made continuous progress in the delivery of antisense nucleic acid structural modifications in vivo and the treatment of liver cancer

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2023-07-13 Revised:2023-07-13 Accepted:2023-07-13 Online:2023-07-31 Published:2023-08-07

Abstract

Supporting:

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The team of Prof. Zhenjun Yang have made continuous progress in the delivery of antisense nucleic acid structural modifications in vivo and the treatment of liver cancer[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 598-599.

The team of Prof. Zhenjun Yang have made continuous progress in the delivery of antisense nucleic acid structural modifications in vivo and the treatment of liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments